Mr. Renaud is Chairman, CEO and President of Redecam Group, a global leader in providing highly engineered industrial air pollution control solutions. A graduate of Franklin College of Switzerland with a Bachelor of Arts in international financial management, Mr. Renaud has been instrumental in securing private equity financings. He is a past director and chairman of a number of publicly traded companies including Sierra Metals Inc.

Dr. Coleman brings a wealth of scientific and business expertise to the board. Currently serving as the President and CEO of Avivo Biomedical Inc., a Vancouver-based biotech firm specializing in groundbreaking technologies facilitating the conversion of blood and organs into universally accepted types. Prior to Avivo, Dr. Coleman co-founded Anandia Labs in 2013, growing it until acquired in 2018 by Aurora Cannabis.

Ms. Greven is currently Managing Director & Head of Loan Distribution Group at ING Capital LLC in NA. Prior to that, Ms. Greven held various Managing Director roles at Rabobank International & Rabo Securities Investment Banking, USA. Ms. Greven also serves on various Boards including Whole & Free Foods LLC and Students for Senegal. She holds an MBA from Columbia Business School, BS from Montana State University and has completed executive educations programs at Harvard Business School and London Business School.

Dr. Huizinga comes to Kane having served as Executive Vice-President of Aurinia Pharmaceuticals Inc. At Aurinia, he led the clinical development of voclosporin which achieved first year sales of US$100 million. Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc., and a clinical investigator at the University of Alberta. Dr. Huizinga holds a PhD in Organizational Leadership, and a Masters in Cclinical Epidemiology.

Dr. Kideckel has nearly two decades of experience in life sciences and corporate advisory which includes industry experience includes leadership positions at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca PLC), He currently serves as Chief Financial Officer (CFO), and Board Director at Rakovina Therapeutics (TSX-V: RKV) (FSE: 7JO) and is the Founder and Principal of the Kideckel Advisory Group Inc. Dr. Kideckel holds a Ph.D. in Neuroscience and Statistics from the University of Toronto’s Institute of Medical Science and an MBA from the Rotman School of Management.

Mr. Rampertab most recently served as Exec VP and CFO for Asensus Surgical, Inc. (NYSE: ASXC), a robotic surgery company with intra-operative augmented intelligence. Prior to that he was Interim CEO, CFO and Secretary for Zomedica Pharmaceuticals Corp. (NYSE: ZOM; TSXV: ZOM), a veterinary health company creating diagnostics and therapeutics. Before joining Zomedica, Mr. Rampertab served as CFO and Secretary at Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a thermal ablation medical device company. Mr. Rampertab is a CPA, CA and holds an MBA and BSc in Molecular Genetics and Molecular Biology.